Table 5 Achievement of Piedmont Region clinical practice guidelines quality-of-care standards in 2002 and 2004, and effects of year, Piedmont Region, Italy
Results | Effect of year (adjusted* OR and 95%CI) 2002 vs2004 | ||||
|---|---|---|---|---|---|
2002 | 2004 | ||||
N and % | Missing | N and % | Missing | ||
% of malignant lesions with cytological or histological pre-operative diagnosis | 297/513 | 48 | 329/495 | 65 | 0.64 (0.49-0.85) |
(57.9%) | (8.6%) | (66.5%) | (11.6%) | ||
% BCS in pT1, unifocal | 231/268 | 0 | 253/272 | 0 | 0.41 (0.22-0.75) |
(86.2%) | (93.0%) | ||||
% BCS with free margins (> 1 mm) | 312/368 | 33 | 348/387 | 33 | 0.65 (0.41-1.01) |
(84.8%) | (8.2%) | (89.9%) | (7.9%) | ||
% single surgery after diagnosis | 332/369 | 4 | 342/376 | 8 | 1.02 (0.24-5.91) |
(90.0%) | (1.1%) | (91.0%) | (2.1%) | ||
% frozen section in lesions ≤ 10 mm | 55/97 | 1 | 85/113 | 0 | 0.32 (0.16-0.65) |
(56.7%) | (1.0%) | (75.2%) | |||
% of patients with invasive lesion treated with axillary clearance or SLN technique | 433/468 | 0 | 460/478 | 1 | 0.28 (0.10-0.85) |
(92.5%) | (96.2%) | (0.2%) | |||
% of patients treated with axillary clearance with > 9 lymph nodes | 317/336 | 4 | 245/268 | 4 | 1.71 (0.89-3.31) |
(94.3%) | (1.2%) | (91.4%) | (1.5%) | ||
% with NO dissection among CIS patients** | 115/123 | 0 | 98/104 | 0 | 0.60 (0.14-2.50) |
(93.5) | (94.2%) | ||||
% correct identification of SLN | 118/126 | 30 | 215/219 | 54 | 0.46 (0.18-1.05) |
(93.6%) | (19.2%) | (98.2%) | (19.8%) | ||
% histopathological grading available | 455/462 | 18 | 466/469 | 17 | 0.34 (0.08-1.42) |
(98.5%) | (3.7%) | (99.4%) | (3.5%) | ||
% hormonal receptor availability | 455/471 | 9 | 446/473 | 13 | 1.80 (0.94-3.48) |
(96.6%) | (1.8%) | (94.3%) | (2.7%) | ||
% immediate reconstruction after mastectomy | 41/154 | 4 | 30/137 | 2 | 1.16 (0.63-2.16) |
(26.6%) | (2.5%) | (21.9%) | (1.4%) | ||
% radiotherapy in patients treated with BCS | 341/389 | 0 | 362/412 | 0 | 1.01 (0.60-1.5) |
(87.7%) | (87.9%) | ||||
% of eligible patients that receive hormonal therapy | 319/338 | 0 | 332/354 | 0 | 1.01 (0.69-1.42) |
(94.3%) | (93.8%) | ||||